ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer.
- DOI
- 10.1016/j.annonc.2026.08.003
- Published
- 2026 Aug 19
- Container
- Annals of oncology : official journal of the European Society for Medical Oncology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.annonc.2026.08.003,
title = {ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer.},
author = {Conroy T and Ducreux M and ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org},
year = {2026},
journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
doi = {10.1016/j.annonc.2026.08.003},
url = {https://doi.org/10.1016/j.annonc.2026.08.003}
}RIS
TY - JOUR TI - ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer. AU - Conroy T AU - Ducreux M AU - ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org PY - 2026 JO - Annals of oncology : official journal of the European Society for Medical Oncology DO - 10.1016/j.annonc.2026.08.003 UR - https://doi.org/10.1016/j.annonc.2026.08.003 ER -
APA
T, C., M, D., & clinicalguidelines@esmo.org, E. G. C. E. A. (2026). ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.08.003
Source records
- pubmed · retrieved 2026-09-25T11:30:21.789Z
- europe-pmc · retrieved 2026-09-25T11:30:21.794Z